Takeda invests in microdose tech collaborator Presage Biosciences

By Gareth Macdonald

- Last updated on GMT

Related tags Cancer Pharmacology

Takeda invests in Presage
Takeda invests in Presage
Takeda has invested in Presage Biosciences whose tech platform is designed to let pharmas test multiple cancer drug combinations in a single trial.

The investment – terms of which have not been disclosed – was conducted through the Japanese drugmaker’s Takeda Ventures venture capital arm and reflects the potential of Presage’s approach according to CEO Graeme Martin.

Presage’s CIVO technology holds promise to better translate preclinical discoveries to patients, particularly in the field of novel cancer drug combinations​.”

According to Presage, the CIVO platform is designed to help sponsors better predict patient response – and likely efficacy - in late phase clinical trials based on data generated during preclinical or first-in-human studies.

The platform consists of an arrayed microinjection system that enables simultaneous delivery of micro-doses of candidate drugs at defined positions on a tumour. It employs automated image analysis to evaluate tumour response.  


In April this year Seattle-based Presage announced, in collaboration with partner Celgene, that response to drugs delivered using the CIVO system accurately predicts systemic response​.

Tokyo-headquartered Takeda has worked with Presage since 2012 when its subsidiary – Millennium Pharmaceuticals – signed a cancer research agreement also focused on assessing the CIVO system.

Under that deal the firms have been evaluating hundreds of different combinations of drugs and preclinical models to guide clinical decision-making on Takeda’s pipeline agents.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more